Indeed, studies in humans demonstrated that lapatinib is useful in patients with triple-negative breast tumors, by activating NF-kB and the anti-apoptotic Bcl-2 protein [43], sensitizing tumor cells to the annexin A6 upregulation [44] and inducing apoptosis [45]. Here, ANXA6 is linked to neoplasm.